Melanoma & Skin Cancer

Zeynep Eroglu, MD, discusses the implications of using triplet vs doublet regimens in patients with melanoma who have symptomatic brain metastases.

Darovasertib was safe and active in the neoadjuvant setting for patients with uveal melanoma.

FDA grants type A meeting to discuss RP1 BLA in melanoma, CBP/p300 bromodomain inhibitor gets fast track status in NSCLC, and more.

Ahmad Tarhini, MD, PhD, discussed the rationale for evaluating preoperative pembrolizumab plus vidutolimod in macroscopic, resectable stage III melanoma.

The FDA scheduled a Type A meeting with the developer of RP1 to discuss the CRL that was granted to RP1 plus nivolumab for advanced melanoma.

In case you missed any, below is a recap of every OncLive On Air episode that aired in August 2025.

Paul Nathan, MBBS, PhD, MRCP, details the rationale for evaluating roginolisib in patients with advanced or metastatic ocular or uveal melanoma.

Vepdegestrant NDA under FDA review in ESR1-mutated breast cancer, Oncomine Dx Target Test gets greenlit as zongertinib companion diagnostic in NSCLC.

Nemvaleukin alfa produced a disease control rate of 50% in advanced melanoma and RCC.

Early data showing tolerability and improved OS with roginolisib in metastatic uveal melanoma support its ongoing evaluation in the phase 2 OCULE-01 trial.

Neoadjuvant vidutolimod plus pembrolizumab showed promising activity in stage III resectable melanoma.

Zeynep Eroglu, MD, discusses management strategies for safe and effective use of encorafenib, binimetinib,and nivolumab in BRAF V600–mutant melanoma.

Zeynep Eroglu, MD, discusses the potential PFS benefit with encorafenib plus binimetinib and nivolumab in BRAF V600–mutant melanoma with symptomatic brain metastases.

Zeynep Eroglu, MD, discusses the rationale for evaluating encorafenib plus binimetinib and nivolumab in BRAF V600-mutant melanoma with brain metastases.

The off-the-shelf therapeutic cancer vaccine plus pembrolizumab improved PFS vs pembrolizumab alone in advanced melanoma.

Janice Mehnert, MD, discusses the rationale for incorporating IL-6 receptor blockade into a combination with checkpoint inhibition for patients with advanced melanoma.

Janice Mehnert, MD, discusses the rationale for adding IL-6 inhibition to an ICI backbone and data with sarilumab plus ICIs in advanced melanoma.

The top 5 OncLive videos of the week cover insights in multiple myeloma, breast cancer, melanoma, and CLL/SLL.

RP1 BLA in advanced melanoma receives CRL from FDA, generic ibrutinib tablets gets green light for B-cell malignancies, and more.

Among patients with advanced melanoma and the target HLA type—representing 80% of the study population—treatment with iSCIB1+ yielded an ORR of 69%.

The FDA has issued a complete response letter for RP1 plus nivolumab for advanced melanoma after a PD-1 inhibitor–containing regimen.

Piotr Rutkowski, MD, discusses a trial evaluating the nivolumab biosimilar JPB898 plus ipilimumab in stage III or metastatic stage IV melanoma.

The top 5 OncLive videos of the week cover insights in ovarian cancer, RCC, melanoma, non–small cell lung cancer, and non–muscle-invasive bladder cancer.

The combination of sarilumab, ipilimumab, nivolumab, and relatlimab displayed activity in patients with stage III or IV melanoma.

The top 5 OncLive videos of the week cover insights in ovarian cancer, RCC, melanoma, non–small cell lung cancer, and non–muscle-invasive bladder cancer.